Imagion Biosystems Ltd (IBX) - Total Assets
Based on the latest financial reports, Imagion Biosystems Ltd (IBX) holds total assets worth AU$932.48K AUD (≈ $659.79K USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See IBX book value for net asset value and shareholders' equity analysis.
Imagion Biosystems Ltd - Total Assets Trend (2014–2024)
This chart illustrates how Imagion Biosystems Ltd's total assets have evolved over time, based on quarterly financial data.
Imagion Biosystems Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Imagion Biosystems Ltd's total assets of AU$932.48K consist of 99.4% current assets and 0.7% non-current assets.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 95.3% |
| Accounts Receivable | AU$886.00 | 0.0% |
| Inventory | AU$0.00 | 0.0% |
| Property, Plant & Equipment | AU$18.27K | 0.7% |
| Intangible Assets | AU$0.00 | 0.0% |
| Goodwill | AU$0.00 | 0.0% |
Asset Composition Trend (2014–2024)
This chart illustrates how Imagion Biosystems Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Imagion Biosystems Ltd stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Imagion Biosystems Ltd's current assets represent 99.4% of total assets in 2024, an increase from 48.0% in 2014.
- Cash Position: Cash and equivalents constituted 95.3% of total assets in 2024, up from 48.0% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2014.
- Asset Diversification: The largest asset category is property, plant & equipment at 0.7% of total assets.
Imagion Biosystems Ltd Competitors by Total Assets
Key competitors of Imagion Biosystems Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Sonic Healthcare Ltd
AU:SHL
|
Australia | AU$17.03 Billion |
|
Eurofins-Cerep SA
PA:ALECR
|
France | €84.58 Million |
|
Inoviq Ltd
AU:IIQ
|
Australia | AU$24.52 Million |
|
Bcal Diagnostics Ltd
AU:BDX
|
Australia | AU$7.17 Million |
|
Integral Diagnostics Ltd
AU:IDX
|
Australia | AU$1.43 Billion |
|
Australian Clinical Labs Ltd
AU:ACL
|
Australia | AU$562.50 Million |
|
Monash Ivf Group Ltd
AU:MVF
|
Australia | AU$510.21 Million |
|
Cryosite Ltd
AU:CTE
|
Australia | AU$19.46 Million |
Imagion Biosystems Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.19 | 0.09 | 2.68 |
| Quick Ratio | 0.19 | 0.09 | 2.68 |
| Cash Ratio | 0.00 | 0.00 | 2.48 |
| Working Capital | AU$-3.88 Million | AU$-5.29 Million | AU$2.94 Million |
Imagion Biosystems Ltd - Advanced Valuation Insights
This section examines the relationship between Imagion Biosystems Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.84 |
| Latest Market Cap to Assets Ratio | 2.10 |
| Asset Growth Rate (YoY) | -38.9% |
| Total Assets | AU$2.80 Million |
| Market Capitalization | $5.90 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Imagion Biosystems Ltd's assets at a significant premium (2.10x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Imagion Biosystems Ltd's assets decreased by 38.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Imagion Biosystems Ltd (2014–2024)
The table below shows the annual total assets of Imagion Biosystems Ltd from 2014 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | AU$2.80 Million ≈ $1.98 Million |
-38.87% |
| 2023-12-31 | AU$4.59 Million ≈ $3.25 Million |
-54.03% |
| 2022-12-31 | AU$9.98 Million ≈ $7.06 Million |
-29.33% |
| 2021-12-31 | AU$14.12 Million ≈ $9.99 Million |
-0.03% |
| 2020-12-31 | AU$14.12 Million ≈ $9.99 Million |
+189.79% |
| 2019-12-31 | AU$4.87 Million ≈ $3.45 Million |
-6.08% |
| 2018-12-31 | AU$5.19 Million ≈ $3.67 Million |
-32.11% |
| 2017-12-31 | AU$7.64 Million ≈ $5.41 Million |
-37.07% |
| 2016-12-31 | AU$12.14 Million ≈ $8.59 Million |
+1440.45% |
| 2015-12-31 | AU$788.19K ≈ $557.69K |
+132.84% |
| 2014-12-31 | AU$338.51K ≈ $239.52K |
-- |
About Imagion Biosystems Ltd
Imagion Biosystems Limited provides medical imaging technologies using magnetic resonance. It is involved in the nanotechnology; biotechnology; and cancer diagnostics businesses. The company develops MagSense, which completed Phase 1 for the treatment of HER2 breast cancers, as well as advancing the research and development programs for prostate and ovarian cancer. It also develops PrecisionMRX, … Read more